Aridis Pharmaceuticals, Inc.
ARDS
$0.00
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -100.68% | 278.17% | -6.72% | 22.48% | -3.26% |
| Total Depreciation and Amortization | -6.35% | -27.59% | -13.00% | -20.00% | -4.58% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 213.98% | -67.18% | 340.79% | -130.12% | 79.20% |
| Change in Net Operating Assets | 89.10% | -996.59% | 212.60% | -162.27% | 153.74% |
| Cash from Operations | 77.37% | -8.52% | 53.23% | -100.63% | 30.53% |
| Capital Expenditure | -- | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -100.00% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -100.00% | -- | -- | -- | 100.00% |
| Total Debt Issued | -57.14% | -- | -- | -- | -- |
| Total Debt Repaid | -200.00% | 200.00% | -10.00% | -200.00% | -- |
| Issuance of Common Stock | 173,300.00% | -99.95% | -83.67% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 33.12% | -35.22% | -121.15% | 25.18% |
| Cash from Financing | -67.01% | 1,051.33% | -97.62% | 2,091.34% | -298.56% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 101.23% | 65.20% | -254.12% | 150.34% | 23.39% |